204 related articles for article (PubMed ID: 36861035)
1. Investigating the suitability of
McCabe A; Zaheed O; McDade SS; Dean K
Front Cell Dev Biol; 2023; 11():1104514. PubMed ID: 36861035
[TBL] [Abstract][Full Text] [Related]
2. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.
Barnes BM; Nelson L; Tighe A; Burghel GJ; Lin IH; Desai S; McGrail JC; Morgan RD; Taylor SS
Genome Med; 2021 Sep; 13(1):140. PubMed ID: 34470661
[TBL] [Abstract][Full Text] [Related]
3. Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.
Zhu S; Zhang C; Cao D; Bai J; Yu S; Chen J; Wang J; Ren T; Yang J; Yu M; Xiao X; Gong Y; Guan Y; Li P; Yue Y; Yin R; Wang Y; An R; Lou G; Yuan J; Zhang G; Xia X; Yang L; Xiang Y
Oncogene; 2022 May; 41(22):3093-3103. PubMed ID: 35468938
[TBL] [Abstract][Full Text] [Related]
4. Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.
Yoffou PH; Edjekouane L; Meunier L; Tremblay A; Provencher DM; Mes-Masson AM; Carmona E
PLoS One; 2011; 6(6):e20705. PubMed ID: 21695196
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
7. Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes.
McFarlane I; Porter JM; Brownsell E; Ghaoui N; Connolly KC; Herrington CS; Hollis RL
Front Oncol; 2024; 14():1399979. PubMed ID: 38854725
[TBL] [Abstract][Full Text] [Related]
8. Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.
Romero I; Leskelä S; Mies BP; Velasco AP; Palacios J
EJC Suppl; 2020 Aug; 15():1-15. PubMed ID: 33240438
[TBL] [Abstract][Full Text] [Related]
9. Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.
Fleury H; Communal L; Carmona E; Portelance L; Arcand SL; Rahimi K; Tonin PN; Provencher D; Mes-Masson AM
Genes Cancer; 2015 Sep; 6(9-10):378-398. PubMed ID: 26622941
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Histological Subtypes on Outcomes of Stage IV Epithelial Ovarian Cancer.
Zhou J; Wu SG; Wang J; Sun JY; He ZY; Jin X; Zhang WW
Front Oncol; 2018; 8():577. PubMed ID: 30564556
[No Abstract] [Full Text] [Related]
12. Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer.
Watanabe T; Nanamiya H; Endo Y; Kojima M; Nomura S; Furukawa S; Soeda S; Tamura H; Ryufuku M; Tanaka D; Isogai T; Imai JI; Watanabe S; Fujimori K
J Ovarian Res; 2021 Oct; 14(1):129. PubMed ID: 34615547
[TBL] [Abstract][Full Text] [Related]
13. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
14. Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.
Jiang J; Bo D; Chang X; Cheng H; Ye X; Cui H
Int J Clin Exp Med; 2015; 8(11):21303-10. PubMed ID: 26885070
[TBL] [Abstract][Full Text] [Related]
15. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
16. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.
Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL
Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358
[TBL] [Abstract][Full Text] [Related]
17. Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease.
Sauriol A; Simeone K; Portelance L; Meunier L; Leclerc-Desaulniers K; de Ladurantaye M; Chergui M; Kendall-Dupont J; Rahimi K; Carmona E; Provencher DM; Mes-Masson AM
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32784519
[TBL] [Abstract][Full Text] [Related]
18. Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.
Li Y; Jaiswal SK; Kaur R; Alsaadi D; Liang X; Drews F; DeLoia JA; Krivak T; Petrykowska HM; Gotea V; Welch L; Elnitski L
BMC Cancer; 2021 Jul; 21(1):768. PubMed ID: 34215221
[TBL] [Abstract][Full Text] [Related]
19. Wilms' tumor 1 antigen immunoreactivity in epithelial ovarian cancer - diagnostic and prognostic value.
Zarychta E; Lepinay K; Szubert S; Jozwicki J; Misiak J; Brozyna AA; Kosinska-Kaczynska K; Lewandowska A; Malicka E; Makarewicz A; Rhone P; Jozwicki W
Folia Histochem Cytobiol; 2020; 58(3):198-207. PubMed ID: 32960974
[TBL] [Abstract][Full Text] [Related]
20. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.
Gambaro K; Quinn MC; Cáceres-Gorriti KY; Shapiro RS; Provencher D; Rahimi K; Mes-Masson AM; Tonin PN
BMC Cancer; 2015 Mar; 15():135. PubMed ID: 25886299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]